Overview
Open Pulmonary Hypertension → Evidence. Detailed appraisals contains the curated report index; All retrieved records opens the broader literature inventory. Search accepts trial names, drugs, routes, phenotypes and publication or registry identifiers. Drug and disease filters narrow the main population and intervention of interest.
Primary endpoint result separates positive, neutral/negative, mixed, nonconfirmatory, secondary and uncertain comparisons. More filters adds clinical group, overall appraisal including harm signals, publication/study context, report type, population scope and sorting. Primary endpoint findings and overall appraisal answer different questions; inspect both rather than treating a positive surrogate as proof of benefit in every setting.
Open a report for the studied population, route, endpoint, limitations and primary-source links. Trial-family links connect parent trials, substudies, secondary reports, extensions and follow-up. Related reports can share participants and must not be counted as independent cohorts. Open-label and observational reports retain their design labels.
The displayed review date describes the checked evidence corpus. Report counts are not pooled patient totals, and this curated index is not a systematic review of every PH study. Current Evidence provides a separate qualitative drug/class overview with its own explanatory limits.